| Abstrakt: |
Keywords: Biotechnology; Cancer; Cancer Therapy; Drugs and Therapies; Emerging Technologies; Epidermal Growth Factor Receptor; Epidermal Growth Factors; Gastrointestinal Hormone Receptors; Gastrointestinal Hormones; Gold Nanoparticles; Growth Factor Receptors; Health and Medicine; Immunologic Agents; Immunotherapy; Intercellular Signaling Peptides and Proteins; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Membrane Proteins; Monoclonal Antibodies; Nanoparticles; Nanotechnology; Nimotuzumab Therapy; Oncology; Pharmaceuticals; Phosphotransferases; Protein Kinases; Receptor Protein-Tyrosine Kinases; Therapy EN Biotechnology Cancer Cancer Therapy Drugs and Therapies Emerging Technologies Epidermal Growth Factor Receptor Epidermal Growth Factors Gastrointestinal Hormone Receptors Gastrointestinal Hormones Gold Nanoparticles Growth Factor Receptors Health and Medicine Immunologic Agents Immunotherapy Intercellular Signaling Peptides and Proteins Lung Cancer Lung Diseases and Conditions Lung Neoplasms Membrane Proteins Monoclonal Antibodies Nanoparticles Nanotechnology Nimotuzumab Therapy Oncology Pharmaceuticals Phosphotransferases Protein Kinases Receptor Protein-Tyrosine Kinases Therapy 1749 1749 1 09/11/23 20230914 NES 230914 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on lung cancer. Furthermore, in vitro studies were performed using a medium-level EGFR-expressing skin cancer cell (A431, EGFR SP medium sp ) and low-level EGFR-expressing lung cancer cell (A549, EGFR SP low sp ) to evaluate anti-tumor and cellular uptake efficiency via MTT assay and single-particle inductively coupled plasma mass spectrometry (spICP-MS), respectively. [Extracted from the article] |
